NDA 050317 · Pfizer
Lincocin
Lincomycin Hydrochloride · Injection
Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Dec 29, 1964
Approved uses
1
Original approval plus efficacy supplements
Registered trials
154
34 Phase 3, 15 recruiting
FAERS reports
170
105 serious, 13 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including LINCOCIN and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial...
What it is approved for
From the label in effect Mar 10, 2025.
INDICATIONS AND USAGE LINCOCIN is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. LINCOCIN may be administered concomitantly with other antimicrobial agents when indicated. LINCOCIN is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of LINCOCIN and other antibacterial drugs, LINCOCIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Mechanism of Action Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 29, 1964 Original approval
1 products under this application
- LINCOCIN · LINCOMYCIN HYDROCHLORIDE EQ 300MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Lincomycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT00642980 · 3,105 participants · Start Apr 2006 · Primary completion Jun 2011
Drug: Clindamycin; Placebo and 1 more · For: Pregnancy
Sites: Lille, France
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Clindamycin to Reduce Preterm Birth in a Low Resource SettingPivotal-lookingCompleted
Christiana Care Health ServicesAcademic, hospital or other
NCT01800825 · 1,726 participants · Start Jul 2013 · Primary completion Apr 2016
Drug: Clindamycin; Placebo · For: Pregnancy; Prematurity; Preterm Birth and 1 more
Sites: Belagavi, India
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT GelPivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00689117 · 1,649 participants · Start Apr 2008 · Primary completion Apr 2009
Drug: CT Gel; Clindamycin Gel (clindamycin ) and 2 more · For: Acne Vulgaris; Acne
Sites: Birmingham, Alabama; Mobile, Alabama; Hot Springs, Arkansas · 32 sites in all
- A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne VulgarisPivotal-lookingCompleted
Lee's Pharmaceutical LimitedIndustry
NCT03615768 · 1,617 participants · Start Aug 14, 2018 · Primary completion Feb 13, 2020
Drug: Adapalene Gel; Clindamycin Gel · For: Acne Vulgaris
Sites: Nanjing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity54
- dyspnoea12
- diarrhoea11
- rash10
- tachycardia9
- abdominal pain8
- dizziness8
- drug ineffective8
- nausea8
- pain8
- pyrexia8
- vomiting8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 12 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 6 |
| 2012 | 16 |
| 2013 | 11 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 12 |
| 2017 | 13 |
| 2018 | 17 |
| 2019 | 14 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 10 |
| 2024 | 7 |
| 2025 | 4 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Feb 25, 2026
Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Nov 6, 2026
Lincocin, Injection, 10 mL multiple dose vial (NDC 0009-0107-04). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lincocin (Lincomycin HCl)
2024 spending
$997
Beneficiaries
n/a
11 claims
Per beneficiary
n/a
$13.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,724 |
| 2021 | $1,777 |
| 2022 | $1,056 |
| 2023 | $950 |
| 2024 | $997 |
Part B: Lincocin* (Lincomycin HCL*) · HCPCS J2010
2024 spending
$232K
Beneficiaries
11,186
16,070 claims
Per beneficiary
$21
2024 ASP limit $9.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $352,794 |
| 2021 | $299,783 |
| 2022 | $268,881 |
| 2023 | $258,596 |
| 2024 | $231,776 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antibiotics for the treatment of COVID-19.
Popp M, Stegemann M, Riemer M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological studies with lincomycin in late pregnancy.
Duignan NM, Andrews J, Williams JD · Br Med J 1973 · Clinical Trial, Controlled Clinical Trial
- Single-dose peroperative antibiotic prophylaxis in gastrointestinal surgery.
Griffiths DA, Simpson RA, Shorey BA, et al. · Lancet 1976 · Clinical Trial, Randomized Controlled Trial
- [7-Chloro-7-deoxy-lincomycin in oto-rhino-laryngology].
Boniver R · Rev Med Liege 1972 · Clinical Trial
- The treatment of chronic osteomyelitis with clindamycin.
Pontifex AH, McNaught DR · Can Med Assoc J 1973 · Clinical Trial
- Prophylaxis against anaerobic sepsis in bowel surgery.
Keighley MR, Crapp AR, Burdon DW, et al. · Br J Surg 1976 · Clinical Trial, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.